|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2000, Vol. 96, No. 7, pp. 2419-2425
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
In vivo CAMPATH-1H prevents graft-versus-host disease following
nonmyeloablative stem cell transplantation
Panagiotis D. Kottaridis,
Donald W. Milligan,
Rajesh Chopra,
Ronjon K. Chakraverty,
Suparno Chakrabarti,
Stephen Robinson,
Karl Peggs,
Stephanie Verfuerth,
Ruth Pettengell,
Judith C. W. Marsh,
Stephen Schey,
Premini Mahendra,
Gareth J. Morgan,
Geoff Hale,
Herman Waldmann,
M. Carmen Ruiz de Elvira,
Catherine D. Williams,
Stephen Devereux,
David C. Linch,
Anthony H. Goldstone, and
Stephen Mackinnon
From the Departments of Hematology, University College
London Hospital, London, England; Heartlands Hospital, Birmingham,
England; Christie Hospital, Manchester, England; St George's Hospital,
London, England; Guy's Hospital, London, England; Queen Elizabeth
Hospital, Birmingham, England; Leeds General Infirmary, Leeds, England,
and Therapeutic Antibody Centre, University of Oxford, Oxford,
England.
A novel nonmyeloablative conditioning regimen was investigated in
44 patients with hematologic malignancies. The median patient age was
41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning
consisted of CAMPATH-1H, 20 mg/day on days  8 to 4; fludarabine, 30 mg/m2 on days 7 to 3; and melphalan, 140 mg/m2 on day 2. Thirty-six recipients received
unmanipulated granculocyte colony-stimulating factor-mobilized
peripheral blood stem cells from HLA-identical siblings, and 8 received
unmanipulated marrow from matched unrelated donors. GVHD prophylaxis
was with cyclosporine A alone for 38 patients and cyclosporine A plus
methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable
patients had sustained engraftment. Results of chimerism analysis using
microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were
mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete
remission or with no evidence of disease progression. Seven patients
relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were
no cases of grades III-IV acute GVHD. Only 2 patients developed grade
II acute GVHD, and only 1 had chronic GVHD. The estimated probability
of nonrelapse mortality was 11%. Although longer follow-up is needed
to establish the long-term remission rates, this study demonstrates
that this nonmyeloablative preparative regimen is associated with
durable engraftment, minimal toxicity, and low incidence of GVHD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al.
Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood,
June 1, 2007;
109(11):
4698 - 4707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Rizzieri, L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, C. Smith, J. Z. Gong, A. Lagoo, et al.
Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution
J. Clin. Oncol.,
February 20, 2007;
25(6):
690 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Meyer, C. M. Britten, D. Wehler, K. Bender, G. Hess, A. Konur, U. F. Hartwig, T. C. Wehler, A. J. Ullmann, C. Gentilini, et al.
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation
Blood,
January 1, 2007;
109(1):
374 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Zenz, M. Ritgen, P. Dreger, A. Krober, T. F. Barth, R. Schlenk, S. Bottcher, M. J. Hallek, M. Kneba, D. Bunjes, et al.
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia
Blood,
September 15, 2006;
108(6):
2127 - 2130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pirson, F. Baron, N. Meuris, O. Giet, E. Castermans, R. Greimers, I. Di Stefano, A. Gothot, and Y. Beguin
Despite Inhibition of Hematopoietic Progenitor Cell Growth In Vitro, the Tyrosine Kinase Inhibitor Imatinib Does Not Impair Engraftment of Human CD133+ Cells into NOD/SCID{beta}2mNull Mice
Stem Cells,
July 1, 2006;
24(7):
1814 - 1821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. I. Marks, et al.
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
Blood,
February 15, 2006;
107(4):
1724 - 1730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chalandon, S. Degermann, J. Villard, L. Arlettaz, L. Kaiser, S. Vischer, S. Walter, M. H. M. Heemskerk, R. A. W. van Lier, C. Helg, et al.
Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications
Blood,
January 1, 2006;
107(1):
389 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tauro, C. Craddock, K. Peggs, G. Begum, P. Mahendra, G. Cook, J. Marsh, D. Milligan, A. Goldstone, A. Hunter, et al.
Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia
J. Clin. Oncol.,
December 20, 2005;
23(36):
9387 - 9393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Feigin
Prospects for the Future of Child Health Through Research
JAMA,
September 21, 2005;
294(11):
1373 - 1379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, F. Zallio, J. Mariotti, L. Farina, M. Bregni, P. Valagussa, F. Ciceri, A. Bacigalupo, A. Dodero, M. Lucesole, et al.
Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies
J. Clin. Oncol.,
September 20, 2005;
23(27):
6690 - 6698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. van Besien, A. Artz, S. Smith, D. Cao, S. Rich, L. Godley, D. Jones, P. Del Cerro, D. Bennett, B. Casey, et al.
Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome
J. Clin. Oncol.,
August 20, 2005;
23(24):
5728 - 5738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, M. Lalancette, R. Szydlo, M. Gilleece, K. Peggs, S. Mackinnon, G. Juliusson, L. Ahlberg, A. Nagler, A. Shimoni, et al.
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
Blood,
June 1, 2005;
105(11):
4532 - 4539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rao, P. J. Amrolia, A. Jones, C. M. Cale, P. Naik, D. King, G. E. Davies, H. B. Gaspar, and P. A. Veys
Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen
Blood,
January 15, 2005;
105(2):
879 - 885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Morris, K. Thomson, C. Craddock, P. Mahendra, D. Milligan, G. Cook, G. M. Smith, A. Parker, S. Schey, R. Chopra, et al.
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
Blood,
December 15, 2004;
104(13):
3865 - 3871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kami, A. Makimoto, Y. Heike, and Y. Takaue
Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies
Jpn. J. Clin. Oncol.,
December 1, 2004;
34(12):
707 - 716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Carroll, D. BuchBarker, R. Schwartz, M. E. Agha, C. Tompkins, K. Baileys, K. O'Connell, A. D. Donnenberg, and A. M. Yeager
Infection Is the Major Cause of Mortality after Nonmyeloablative Unrelated Bone Marrow Transplantation with Alemtuzumab, Fludarabine and Melphalan.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
5165 - 5165.
[Abstract]
|
|
|
|
|
|
|
T. Iwasaki
Recent Advances in the Treatment of Graft-Versus-Host Disease
Clin. Med. Res.,
November 1, 2004;
2(4):
243 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baron, J. E. Baker, R. Storb, T. A. Gooley, B. M. Sandmaier, M. B. Maris, D. G. Maloney, S. Heimfeld, D. Oparin, E. Zellmer, et al.
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
Blood,
October 15, 2004;
104(8):
2254 - 2262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Blood,
September 1, 2004;
104(5):
1550 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, A. Dodero, F. Zallio, D. Caracciolo, M. Casini, M. Bregni, F. Narni, F. Patriarca, M. Boccadoro, F. Benedetti, et al.
Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells
J. Clin. Oncol.,
June 1, 2004;
22(11):
2172 - 2176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol.,
March 15, 2004;
22(6):
1136 - 1151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Peggs, K. Thomson, D. P. Hart, J. Geary, E. C. Morris, K. Yong, A. H. Goldstone, D. C. Linch, and S. Mackinnon
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
Blood,
February 15, 2004;
103(4):
1548 - 1556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Carvallo, N. Geller, R. Kurlander, R. Srinivasan, O. Mena, T. Igarashi, L. M. Griffith, W. M. Linehan, and R. W. Childs
Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors
Blood,
February 15, 2004;
103(4):
1560 - 1563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Thomson, S. Ings, M. Watts, S. Mackinnon, and K. S. Peggs
CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion
Blood,
January 15, 2004;
103(2):
743 - 743.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Faulkner, C. Craddock, J. L. Byrne, P. Mahendra, A. P. Haynes, H. G. Prentice, M. Potter, A. Pagliuca, A. Ho, S. Devereux, et al.
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
Blood,
January 15, 2004;
103(2):
428 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Casper, W. Knauf, T. Kiefer, D. Wolff, B. Steiner, U. Hammer, R. Wegener, H.-D. Kleine, S. Wilhelm, A. Knopp, et al.
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
Blood,
January 15, 2004;
103(2):
725 - 731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Hogan, M. Maris, B. Storer, B. M. Sandmaier, D. G. Maloney, H. G. Schoch, A. E. Woolfrey, H. M. Shulman, R. Storb, and G. B. McDonald
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients
Blood,
January 1, 2004;
103(1):
78 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.C. Taussig, A.J. Davies, J.D. Cavenagh, H. Oakervee, D. Syndercombe-Court, S. Kelsey, J.A.L. Amess, A.Z.S. Rohatiner, T.A. Lister, and M.J. Barnett
Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting
J. Clin. Oncol.,
August 15, 2003;
21(16):
3060 - 3065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, J.-O. Bay, C. Faucher, B. Choufi, K. Bilger, O. Tournilhac, N. Vey, A.-M. Stoppa, D. Coso, C. Chabannon, et al.
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
Blood,
July 15, 2003;
102(2):
470 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Morris, P. Rebello, K. J. Thomson, K. S. Peggs, C. Kyriakou, A. H. Goldstone, S. Mackinnon, and G. Hale
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
Blood,
July 1, 2003;
102(1):
404 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Wulf, K.-L. Luo, M. A. Goodell, and M. K. Brenner
Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation
Blood,
March 15, 2003;
101(6):
2434 - 2439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ratzinger, J. L. Reagan, G. Heller, K. J. Busam, and J. W. Young
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
Blood,
February 15, 2003;
101(4):
1422 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Finke, C. Schmoor, H. Lang, K. Potthoff, and H. Bertz
Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti-T Lymphocyte Globulin
J. Clin. Oncol.,
February 1, 2003;
21(3):
506 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y. L. Ho, M. Kenyon, I. El-Hemaidi, S. Devereux, A. Pagliuca, and G. J. Mufti
Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200
Blood,
January 15, 2003;
101(2):
779 - 780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Or, M. Y. Shapira, I. Resnick, A. Amar, A. Ackerstein, S. Samuel, M. Aker, E. Naparstek, A. Nagler, and S. Slavin
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase
Blood,
January 15, 2003;
101(2):
441 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho
Myelodysplastic Syndrome
Hematology,
January 1, 2003;
2003(1):
176 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. I. Marks, R. Lush, J. Cavenagh, D. W. Milligan, S. Schey, A. Parker, F. J. Clark, L. Hunt, J. Yin, S. Fuller, et al.
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation
Blood,
October 16, 2002;
100(9):
3108 - 3114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Perez-Simon, P. D. Kottaridis, R. Martino, C. Craddock, D. Caballero, R. Chopra, J. Garcia-Conde, D. W. Milligan, S. Schey, A. Urbano-Ispizua, et al.
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
Blood,
October 16, 2002;
100(9):
3121 - 3127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al.
Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
J. Clin. Oncol.,
October 1, 2002;
20(19):
4022 - 4031.
[Abstract]
| |
